Younes Maged, Aquilina Gabriele, Degen Gisela, Engel Karl-Heinz, Fowler Paul, Frutos Fernandez Maria Jose, Fürst Peter, Gundert-Remy Ursula, Gürtler Rainer, Husøy Trine, Manco Melania, Mennes Wim, Passamonti Sabina, Moldeus Peter, Shah Romina, Waalkens-Berendsen Ine, Wright Matthew, Barat Baviera José Manuel, Gott David, Herman Lieve, Leblanc Jean-Charles, Wölfle Detlef, Entrena Jaime Aguilera, Gagliardi Gabriele, Rincon Ana Maria, Ruggeri Laura, Smeraldi Camilla, Tard Alexandra, Castle Laurence
EFSA J. 2024 Jun 28;22(6):e8822. doi: 10.2903/j.efsa.2024.8822. eCollection 2024 Jun.
The EFSA Panel on Food Additive and Flavourings (FAF Panel) provides a scientific opinion on the safety of soy leghemoglobin from genetically modified as a food additive in accordance with Regulation (EC) No 1331/2008. The proposed food additive, LegH Prep, is intended to be used as a colour in meat analogue products. The yeast strain MXY0541 has been genetically modified to produce soy leghemoglobin; the safety of the genetic modification is under assessment by the EFSA GMO Panel (EFSA-GMO-NL-2019-162). The amount of haem iron provided by soy leghemoglobin from its proposed uses in meat analogue products is comparable to that provided by similar amounts of different types of meat. The exposure to iron from the proposed food additive, both at the mean and 95th percentile exposure, will be below the 'safe levels of intake' established by the NDA Panel for all population groups. Considering that the components of the proposed food additive will be digested to small peptide, amino acids and haem B; the recipient (non GM) strain qualifies for qualified presumption of safety status; no genotoxicity concern has been identified and no adverse effects have been identified at the highest dose tested in the available toxicological studies, the Panel concluded that there was no need to set a numerical acceptable daily intake (ADI) and that the food additive does not raise a safety concern at the proposed use in food category 12.9 and maximum use level. The Panel concluded that the use of soy leghemoglobin from genetically modified MXY0541 as a new food additive does not raise a safety concern at the proposed use and use level. This safety evaluation of the proposed food additive remains provisional subject to the ongoing safety assessment of the genetic modification of the production strain by the GMO Panel (EFSA-GMO-NL-2019-162).
欧洲食品安全局食品添加剂和调味剂小组(FAF小组)根据欧盟法规(EC)No 1331/2008,就转基因大豆豆血红蛋白作为食品添加剂的安全性提供了科学意见。拟议的食品添加剂LegH Prep旨在用作肉类模拟产品中的色素。酵母菌株MXY0541经过基因改造以生产大豆豆血红蛋白;欧洲食品安全局转基因生物小组(EFSA - GMO小组,EFSA - GMO - NL - 2019 - 162)正在对该基因改造的安全性进行评估。拟议将大豆豆血红蛋白用于肉类模拟产品中所提供的血红素铁量,与相似量的不同类型肉类所提供的血红素铁量相当。对于所有人群组,拟议食品添加剂的铁暴露量,无论是平均暴露量还是第95百分位数暴露量,都将低于营养与膳食补充剂小组设定的“安全摄入水平”。考虑到拟议食品添加剂的成分将被消化成小肽、氨基酸和血红素B;受体(非转基因)菌株符合安全合格推定状态;在现有的毒理学研究中,在最高测试剂量下未发现遗传毒性问题,也未发现不良反应,该小组得出结论,无需设定数值化的每日允许摄入量(ADI),并且该食品添加剂在食品类别12.9中的拟议用途和最大使用水平下不会引发安全问题。该小组得出结论,在拟议用途和使用水平下,使用转基因MXY0541生产的大豆豆血红蛋白作为新型食品添加剂不会引发安全问题。对拟议食品添加剂的这一安全评估仍为临时评估,有待转基因生物小组(EFSA - GMO - NL - 2019 - 162)对生产菌株的基因改造进行持续的安全评估。